Business Change in Pharma & Life Sciences

We work alongside your existing teams rather than duplicating them. That can mean partnering with programme leadership, clinical, regulatory, data, technology, HR, communications and learning teams while integrating with platform or implementation partners.

Our role is to connect the business and people agenda to the programme: clarifying value, understanding cross-functional and role-level impacts, preparing the organisation, enabling adoption and building internal capability. We do not replace scientific, clinical, regulatory-authority or technical implementation expertise.

Ideally, before the solution, operating model and programme approach are fully fixed. Early involvement allows leaders to align on the business outcome, test assumptions, understand the functions and roles affected, and design governance and readiness into the programme rather than adding change activity later.

We can also enter during delivery or after go-live when adoption is lagging, but earlier involvement gives the organisation more options and reduces avoidable rework.

Yes. We diagnose what is preventing adoption rather than assuming more communications or training will solve it. The issue may sit in process design, leadership, role clarity, governance, confidence, workload, local variation or the way value has been articulated.

On a global Veeva RIM transformation, Afiniti helped reshape the change approach after early releases had not created sufficient adoption, introducing role-based impacts, leadership activation, Superuser squads and a more structured engagement and sustainment model.

We combine one coherent enterprise direction with function-, role- and location-specific relevance. Global and affiliate teams may share a platform or process, but their responsibilities, timelines, risks and support needs can be very different.

We use stakeholder and impact analysis, personas, local networks, leadership materials, role-based learning and feedback loops to maintain consistency without imposing a one-size-fits-all change journey.

Yes. We focus on the organisational capability around AI: value, governance, roles, decision rights, confidence, skills, use cases and responsible adoption. The aim is to help people use AI-enabled insight effectively while keeping expert human judgement, validation and accountability visible.

Our life sciences work includes AI-enabled study design, data and content generation, R&D transformation and AI-aided change intelligence. We do not position AI as a substitute for scientific or regulated decision-making.

We connect the regulatory intent to the actual work people must do differently: roles, decisions, handoffs, systems, behaviours and evidence. Change impact assessment informs targeted engagement, learning and support, while leadership and local networks reinforce the new process after deployment.

We also build sustainment into the design through Superusers, communities, reusable toolkits, governance and measurement, rather than treating go-live as the end of the change.

We align measurement to the outcome the programme needs to achieve. Depending on the engagement, that can include leadership alignment, impact and readiness evidence, adoption and proficiency, engagement effectiveness, use of new processes, capability measures and realised business benefits.

Our 6Lever™ Change Readiness Assessment, impact analysis and change dashboards help leaders see where risk is concentrated, which interventions require attention and whether the future state is becoming the normal way of working.

That is an explicit objective of how we work. We intentionally transfer knowledge, coach leaders and internal change teams, build networks, and leave behind practical methods, tools and governance that your organisation can continue to use.

Successful delivery should leave the client stronger and more capable, not dependent on an external consultancy for every future release or programme.